Neovasc to Participate in 2021 Benzinga Healthcare Small Cap Conference
September 23 2021 - 09:05AM
via NewMediaWire -- Neovasc, Inc. (“Neovasc” or the “Company”)
(NASDAQ,TSX: NVCN) today announced that its management team will be
participating in the 2021 Benzinga Healthcare Small Cap Conference
to be held September 29-30, 2021. Bill Little, Neovasc’s
Chief Operating Officer, will give a presentation on Wednesday,
September 29 at 4:00 pm EDT. A link to the live webcast of
the presentation will be available in the Investor Relations
section of the Neovasc website
at https://www.neovasc.com/investors/. The recording will be
archived for 90 days.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops,
manufactures and markets products for the rapidly growing
cardiovascular marketplace. The Company is a leader in the
development of minimally invasive transcatheter mitral valve
replacement technologies, and minimally invasive devices for the
treatment of refractory angina. Its products include the Neovasc
Reducer™, for the treatment of refractory angina, which is not
currently commercially available in the United States and has been
commercially available in Europe since 2015, and Tiara™, for the
transcatheter treatment of mitral valve disease, which is currently
under clinical investigation in the United States, Canada, Israel,
and Europe. For more information, visit: www.neovasc.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and applicable Canadian securities
laws that may not be based on historical fact. When used herein,
the words “expect”, “anticipate”, “estimate”, “may”, “will”,
“should”, “intend,” “believe”, and similar expressions, are
intended to identify forward-looking statements. Forward-looking
statements may involve, but are not limited to, expectations as to
the future growth of the Company, the expansion of its product
range and the growing cardiovascular marketplace. Forward-looking
statements are based on estimates and assumptions made by the
Company in light of its experience and its perception of historical
trends, current conditions and expected future developments, as
well as other factors that the Company believes are appropriate in
the circumstances. Many factors could cause the Company’s actual
results, performance or achievements to differ materially from
those expressed or implied by the forward-looking statements,
including those described in the “Risk Factors” section of the
Company’s Annual Report on Form 20-F and in the Management’s
Discussion and Analysis for the three and six months ended June 30,
2019 (copies of which may be obtained at www.sedar.com or
www.sec.gov). These factors should be considered carefully, and
readers should not place undue reliance on the Company’s
forward-looking statements. The Company has no intention and
undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contacts
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.617.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.677.1839
Sean.Leous@westwicke.com
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Mar 2023 to Mar 2024